Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

The majority of patients with chronic myeloid leukemia are successfully managed with life-long treatment with tyrosine kinase inhibitors. In patients in chronic phase, other malignancies are among the most common causes of death, raising concerns on the relationship between these deaths and the off-...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Haematologica
Päätekijät: Gugliotta, Gabriele, Castagnetti, Fausto, Breccia, Massimo, Albano, Francesco, Iurlo, Alessandra, Intermesoli, Tamara, Abruzzese, Elisabetta, Levato, Luciano, D’Adda, Mariella, Pregno, Patrizia, Cavazzini, Francesco, Stagno, Fabio, Martino, Bruno, La Barba, Gaetano, Sorà, Federica, Tiribelli, Mario, Bigazzi, Catia, Binotto, Gianni, Bonifacio, Massimiliano, Caracciolo, Clementina, Soverini, Simona, Foà, Robin, Cavo, Michele, Martinelli, Giovanni, Pane, Fabrizio, Saglio, Giuseppe, Baccarani, Michele, Rosti, Gianantonio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Ferrata Storti Foundation 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685244/
https://ncbi.nlm.nih.gov/pubmed/28572163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.169532
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia